Addex Therapeutics (ADXN) Net Margin (2019 - 2025)
Addex Therapeutics' (ADXN) quarterly Net Margin came in at 2112331.45% in Q4 2025, down 275404233.0% year-over-year from N/an in Q4 2024, and down 641.02% quarter-over-quarter from 390432.05% in Q3 2025.
Powered by 
Analysis
Addex Therapeutics (ADXN) Net Margin (2019 - 2025) Analysis & Trends
Addex Therapeutics has disclosed Net Margin across 7 years of filings, most recently posting 2112331.45% for Q4 2025.
- In Q4 2025, Net Margin fell 275404233.0% year-over-year to 2112331.45%; the TTM figure through Dec 2025 stood at 347979.15% (up 34346795.0% YoY), while the FY2025 annual figure was 22448.44%, down 2419448.0% from the prior year.
- Net Margin came in at 2112331.45% for Q4 2025 at Addex Therapeutics, down from 390432.05% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 641710.88% in Q4 2024 to a low of 2112331.45% in Q4 2025.
- Average Net Margin over 5 years is 59664.94%, with a median of 22.64% recorded in 2021.
- Year-over-year, Net Margin soared 64096471 bps in 2024 and slumped 275404233 bps in 2025.
- Over 5 years, Net Margin stood at 536.98% in 2021, then soared by 54 bps to 829.3% in 2022, then declined by 10 bps to 746.17% in 2023, then jumped by 85901 bps to 641710.88% in 2024, then plunged by 429 bps to 2112331.45% in 2025.
- Per Business Quant data, the three most recent Net Margin figures were 2112331.45% in Q4 2025, 390432.05% in Q3 2025, and 641710.88% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.31 Bn | 620.55 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 445.49 Bn | 438.92 Bn | 12.70 Bn | 21.28% |
| 3 | Merck | 357.41 Bn | 350.27 Bn | 12.21 Bn | -8.05% |
| 4 | Novartis Ag | 267.66 Bn | 259.97 Bn | 11.24 Bn | 22.65% |
| 5 | Pfizer | 156.81 Bn | 145.11 Bn | 10.94 Bn | -1.58% |
| 6 | Sanofi | 52.17 Bn | 44.78 Bn | 10.79 Bn | 2.96% |
| 7 | Revolution Medicines | 42.94 Bn | 42.94 Bn | - | - |
| 8 | Incyte | 24.61 Bn | 20.07 Bn | 1.57 Bn | 34.98% |
| 9 | United Therapeutics | 21.31 Bn | 18.64 Bn | 683.80 Mn | 42.51% |
| 10 | Addex Therapeutics | 6.15 Mn | 6.15 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -2,112,331.45% |
| Sep 30, 2025 | 390,432.05% |
| Dec 31, 2024 | 641,710.88% |
| Sep 30, 2024 | -7,295.30% |
| Jun 30, 2024 | 11,171.90% |
| Mar 31, 2024 | -20.87% |
| Dec 31, 2023 | 746.17% |
| Sep 30, 2023 | -7.76% |
| Jun 30, 2023 | -21.56% |
| Mar 31, 2023 | -6.10% |
| Dec 31, 2022 | 829.30% |
| Sep 30, 2022 | 32.46% |
| Jun 30, 2022 | 261.33% |
| Mar 31, 2022 | 280.67% |
| Dec 31, 2021 | 536.98% |
| Sep 30, 2021 | 12.23% |
| Jun 30, 2021 | 12.82% |
| Mar 31, 2021 | -312.67% |
| Dec 31, 2020 | 376.64% |
| Sep 30, 2020 | -555.34% |